LACK OF SINGLE-DOSE DISULFIRAM EFFECTS ON CYTOCHROME P-450 2C9, 2C19, 2D6, AND 3A4 ACTIVITIES: EVIDENCE FOR SPECIFICITY TOWARD P-450 2E1

EVAN D. KHARASCH, DOUGLAS C. HANKINS, CAROLE JUBERT, KENNETH E. THUMMEL, AND JULIE K. TARADAY

Departments of Anesthesiology, Medicinal Chemistry, and Pharmaceutics, University of Washington, Seattle, Washington and the Anesthesiology Service, Puget Sound Veterans Affairs Health Care System, Seattle, Washington

(Received December 18, 1998; accepted February 23, 1999)

This paper is available online at http://www.dmd.org

ABSTRACT:
Disulfiram and its primary metabolite diethyldithiocarbamate are effective mechanism-based inhibitors of cytochrome P-450 2E1 (CYP2E1)\(^1\) in vitro. Single-dose disulfiram diminishes CYP2E1 activity in vivo and has been used to identify CYP2E1 participation in human drug metabolism and prevent CYP2E1-mediated toxification. Specificity of single-dose disulfiram toward CYP2E1 in vivo, however, remains unknown. This investigation determined single-dose disulfiram effects on human CYP 2C9, 2C19, 2D6, and 3A4 activities in vivo. In four randomized crossover experiments, volunteers received isoform-selective probes (oral tolbutamide, methylenedioxy, dextromethorphan, or i.v. midazolam) on two occasions, 10 h after oral disulfiram or after no pretreatment (controls). Plasma and/or urine parent and/or metabolite concentrations were measured by HPLC or gas chromatography-mass spectrometry. CYP2C9, 2C19, 2D6, and 3A4 activities were determined from the tolbutamide metabolic ratio, 4'-hydroxymephenytoin excretion, and dextromethorphan/dextrorphan ratios in urine and midazolam systemic clearance, respectively. Midazolam clearance (670 ± 190 versus 700 ± 240 ml/min, disulfiram versus controls), dextromethorphan/dextrorphan metabolic ratio (0.013 ± 0.033 versus 0.015 ± 0.035), 4'-hydroxymephenytoin excretion (122 ± 22 versus 128 ± 25 μmol), and tolbutamide metabolism excretion (577 ± 157 versus 610 ± 208 μmol) were not significantly altered by disulfiram pretreatment, although the tolbutamide metabolic ratio was slightly diminished after disulfiram (68 ± 17 versus 81 ± 40, \(p < .05\)). Results show that single-dose disulfiram does not cause clinically significant inhibition of human CYP2C9, 2C19, 2D6, and 3A4 activities in vivo. When single-dose disulfiram is used as an in vivo probe for P-450, inhibition of drug metabolism suggests selective involvement of CYP2E1. Single-dose disulfiram should not cause untoward drug interactions from inhibition of other P-450 isoforms.

The metabolism of numerous halogenated xenobiotics used in industrial applications, endogenous compounds, ethanol, and a few drugs such as chlorzoxazone, isoniazid, acetaminophen, and volatile anesthetics is catalyzed by human liver cytochrome P-450 (CYP) 2E1 (Lieber, 1997). Potential consequences of such metabolism include bioactivation resulting in toxification and/or carcinogenesis. One approach for identifying CYP2E1 participation in human xenobiotic biotransformation in vivo is to manipulate CYP2E1 activity, by induction or inhibition, and assess the effect on candidate drug metabolism. When bioactivation portends toxification, the latter approach is preferable. A corollary application of this technique is that CYP2E1 inhibition may be used prophylactically, or possibly postexposure, to prevent CYP2E1-mediated toxification.

Single-dose disulfiram inhibition of CYP2E1 has been explored as an in vivo probe for CYP2E1 participation in biotransformation and as a potential preventative agent against CYP2E1-mediated toxification. Disulfiram and its reduced metabolite diethylthiocarbamate inhibit human liver microsomal CYP2E1 in vitro (Guengerich et al., 1991) and rat CYP2E1 in vivo (Brady et al., 1991). Using chlorzoxazone 6-hydroxylation as a measure of CYP2E1 activity (Peter et al., 1990), disulfiram was found to reduce chlorzoxazone elimination clearance and 6-hydroxychlorzoxazone formation clearance to 15% and 7% of control values, respectively (Kharasch et al., 1993). This established single-dose disulfiram as an effective inhibitor of human CYP2E1 in vivo, a useful probe for delineating CYP2E1 participation in drug disposition and for potential prevention of CYP2E1-mediated toxification. Single-dose disulfiram was subsequently used to establish CYP2E1 participation in human in vivo metabolism of enfurane, sevoflurane, and halothane (Kharasch et al., 1994, 1995, 1996) and to diminish CYP2E1-mediated metabolism of halothane to potentially toxic reactive intermediates (Kharasch et al., 1996).

Although initial in vitro investigations indicated that disulfiram and diethylthiocarbamate were selective, mechanism-based inhibitors of CYP2E1 (Guengerich et al., 1991), their selectivity was subsequently questioned. For example, diethylthiocarbamate was also reported to inhibit human liver microsomal P-450s 2A6 (Yamazaki et al., 1994; Chang et al., 1994; Ono et al., 1996) and 2C19 (Ono et al., 1996) and, at higher concentrations, both 2C8 and 3A3/4 (Chang et al., 1994). Furthermore, although disulfiram efficacy toward CYP2E1 is unquestioned, the in vivo specificity of single-dose disulfiram for only CYP2E1 remains unknown. Accurate interpretation of clinical studies using disulfiram as a (presumably) selective inhibitor of CYP2E1 rests on this identification. Furthermore, before disulfiram can be

Send reprint requests to: Evan D. Kharasch, Department of Anesthesiology, Box 358540, University of Washington, Seattle, WA 98195. E-mail: kharasch@u.washington.edu

\(^1\) Abbreviation used is: TTCA, 2-thiothiazolidine-4-carboxylic acid.
recommended to prevent CYP2E1-mediated drug or xenobiotic bio-activation and toxicity, its safety, vis-a-vis the absence of unwanted and potentially hazardous non-CYP2E1 drug interactions, must be demonstrated. We recently showed that single-dose disulfiram does not inhibit human CYP2A6 activity (coumarin hydroxylation) in vivo (Kharasch et al., 1998). The present investigation determined the effect of single-dose disulfiram on the other human P-450 isoforms responsible for metabolizing the majority of therapeutically used drugs, CYPs 2C9, 2C19, 2D6, and 3A4 (Guengerich, 1995; Wrighton et al., 1996).

Materials and Methods

Patient Selection and Clinical Protocol. Male and nonpregnant female nonsmoking volunteers participated in this investigation after written informed consent was obtained. The investigational protocols were approved by the Institutional Human Subjects Committee. Not all subjects participated in each study pair; group size was determined by prospective power analysis. Subjects were in good health, within 20% of ideal body weight, had no history of hepatic or renal disease, and were taking no prescription medications (excluding a few subjects on oral contraceptives) during the investigation. Subjects abstained from caffeine, grapefruit, grapefruit juice, and ethanol beginning the day before each study day and continuing throughout the period of urine collection. Subjects also abstained from ethanol for 5 days after disulfiram administration. Each substrate probe was studied in a crossover design, with subjects randomly assigned first to the control or disulfiram phase and a washout period of 1 to 2 weeks between phases. Pretreated subjects received 300 mg of disulfiram orally at bedtime, 9 to 10 h before substrate probes, whereas controls received nothing.

CYP3A4 activity was assessed by the clearance of midazolam (Thummel et al., 1994a,b). Subjects received 1 mg i.v. midazolam, and venous blood samples were obtained through an indwelling catheter in the contralateral arm for 12 h after dosing. Plasma was frozen at −20°C for later analysis. Based on the population variability of midazolam disposition (Kassai et al., 1988), 15 subjects (30 ± 5 years, 72 ± 13 kg, 8:7 male/female) were studied to detect a 30% difference in midazolam clearance (α = 0.05, β = 80%). CYP3A4 activity was also estimated by the N-deethylation of dextromethorphan to 3-methoxymorphinan (Jaçqz-Aigrain et al., 1993; Ducharme et al., 1996; Jones et al., 1996).

CYP2D6 activity was determined from the metabolism of dextromethorphan (Schmid et al., 1985). Subjects received 30 mg oral dextromethorphan hydrobromide (85.5 μmol of dextromethorphan) with 200 ml of water after an overnight fast, followed 2 h later by a standard breakfast. Urine was collected 0 to 8 h after dextromethorphan, the volume was measured, and an aliquot was frozen at −20°C for metabolite analysis. Forty subjects (28 ± 5 years, 69 ± 12 kg, 20:20 male/female) were studied to detect a 30% difference in dextromethorphan O-deethylation (α = 0.05, β = 80%), based on the population variability of dextromethorphan O-deethylation and the expected incidence of poor metabolizers (Evans et al., 1993).

CYP2C19 activity was determined by the 4′-hydroxylation of S-mephentoin (Whitworth et al., 1993), as described previously (Kupfer and Preisig, 1984; Wedlund et al., 1984). Subjects received racemic mephenytoin (100 mg orally with 200 ml of water; 229 μmol of S-mephenytoin), followed 2 h later by a standard breakfast. Urine was collected from 0 to 8 h after mephenytoin dosing, the volume was measured, and an aliquot was frozen at −20°C for metabolite analysis. Fifteen subjects (30 ± 5 years, 72 ± 13 kg, 8:7 male/female) were studied, based on the calculation that 13 subjects would be needed to detect a 30% difference in mephenytoin metabolism (α = 0.05, β = 80%) using the published population variability of mephenytoin hydroxylation and the expected incidence of poor metabolizers (Wilkinson et al., 1989; Goldstein et al., 1997).

CYP2C9 activity was assessed by the metabolism of tolbutamide to hydroxyltolbutamide and its secondary metabolite carboxyltolbutamide (Brian et al., 1989; Relling et al., 1990), as described previously (Pearl et al., 1987; Veronese et al., 1990). Subjects received tolbutamide (500 mg orally, 1849 μmol) with 200 ml of water after breakfast. Urine was collected from 6 to 12 h after tolbutamide, the volume was measured, and an aliquot was frozen at −20°C for metabolite analysis. Subjects self-administered glucose tablets at regular intervals until the midafternoon urine collection to prevent hypoglycemia. Twenty subjects (29 ± 4 years, 70 ± 12 kg, 9:11 male/female) were studied to detect a 30% difference in tolbutamide metabolic ratio (α = 0.05, β = 80%), based on the population variability of tolbutamide metabolism (Veronese et al., 1993).

Analytical Methods. Dextromethorphan, dextrophan, 3-methoxymorphinan, 3-hydroxymorphinan, levallorphan, tolbutamide, hydroxyltolbutamide, and 4′-hydroxyphenytoin were obtained from Research Biochemicals, Inc. (Natick, MA), carboxyltolbutamide was purchased from UltraFine Chemicals (Manchester, England), and all other chemicals were from Sigma (St. Louis, MO).

Plasma midazolam concentrations were determined by gas chromatography-mass spectrometry as described previously (Thummel, 1994b), with minor modification. Briefly, 1.5 ml of plasma containing the internal standard diazepam (25 ng) and 0.5 ml of 1 M sodium hydroxide was extracted with 2 × 3 ml of ethyl acetate-heptane (1:1, v/v). The combined organic layers were evaporated under nitrogen at 40°C, reconstituted in 75 μl of acetate-heptane, and analyzed on a Hewlett-Packard 5890 series II GC/5972 mass selective detector using a DB-5 capillary column (30 m × 0.32 mm × 0.25 μm film film). The combined head pressure (helium carrier gas) was 25 psi for 1 min and then decreased to 8 psi. The oven temperature was 200°C for 1 min, increased 10°C/min to 280°C, and then to 320°C at 5°C/min. Injector and transfer line temperatures were 290°C and 300°C, respectively. Ions monitored were m/z 283.1 and 310.1 for diazepam and midazolam, respectively. Standard curves were prepared daily (0.1–25 ng/ml) and were linear (r² > 0.99 over 0.1–5 and 0.1–25 ng/ml). The interday variability was 12, 7, and 1% at 0.1, 5, and 25 ng/ml, respectively.

Urine dextromethorphan and metabolite concentrations were determined by HPLC with fluorescence detection as described (Chen et al., 1990), with the following modifications. Urine (1 ml) was incubated overnight at 37°C with 1 ml of 0.1 M potassium acetate buffer (pH 5) containing β-glucuronidase (5000 U/ml), spiked with 5 μg of levallorphan and diluted with 1 ml of saturated sodium carbonate. Samples were twice extracted with 3 ml of diethyl ether/chloroform/isopropanol (20:9:1) by vortexing for 10 min and centrifuged at 2000g for 10 min; organic layers were combined into a 15-ml tared polypropylene screw cap tube containing 200 μl of 0.1 N HCl. Analytes were back-extracted by vortexing for 10 min and centrifuging (2000g, 10 min), and the organic layer was aspirated and the aqueous phase evaporated to dryness under nitrogen at 55°C. Samples were reconstituted in 100 μl of 0.1 N HCl, vortexed, and transferred to an autosampler vial. Chromatography was performed with a Hewlett Packard 1050 HPLC system coupled to a Kratos Spectroflow 980 fluorescence detector (excitation 228 nm, no emission cut-off filter) using a Rainsor Microb phenol column (250 × 4.6 mm, 5 microns). The mobile phase was methanol/acetonitrile/10 mM potassium phosphate (pH 3.5) (20:25:55) at 1.2 ml/min. Analyses were carried out at room temperature. Each sample was injected twice (1 and 10 μl) to ensure that peaks were within the linear range of the detector. Calibration standards were prepared daily using blank urine containing 80 to 10,000 ng/ml dextrophan and 3-hydroxy-morphinan and 8 to 1000 ng/ml dextromethorphan and 3-methoxymorphinan. Peak area ratios were used for analysis of dextromethorphan and dextrophan, and 3-methoxymorphinan and 3-hydroxy-morphinan were quantified from peak height ratios because complete baseline resolution was unattainable in some patients. Standard curves were linear over the concentration ranges used (r² > 0.99, 0.99, 0.98, and 0.96 for dextromethorphan, dextrophan, 3-methoxymorphinan, and 3-hydroxy-morphinan, respectively). Interday coefficients of variation were 25 and 2% at 16 and 1000 ng/ml dextromethorphan, 22 and 15% at 0.3 and 2.5 μg/ml dextrophan, 19 and 2% at 16 and 1000 ng/ml 3-methoxy-morphinan, and 18 and 8% at 0.3 and 2.5 μg/ml 3-hydroxy-morphinan.

The concentration of 4′-hydroxyphenytoin in urine was measured by HPLC with UV detection as described, with minor modification (Xie et al., 1995). Urine (100 μl), water (900 μl), and 50 μl of 0.5 M acetate buffer (pH 5.0, containing 5000 U/ml β-glucuronidase) were incubated in polyethylene tubes at 37°C for 18 h. The hydrolysate was transferred to a glass tube containing 5 μg of phenobarbital and twice extracted by vortexing with 3 ml of diethyl ether. Following centrifugation (2000g, 10 min), the combined organic layers were evaporated to dryness at 45°C under nitrogen, reconstituted in 50 μl of mobile phase, and transferred to an autosampler vial. Chromatography was performed at room temperature on an HP 1050 HPLC.
system with variable wavelength UV detector at 204 nm, using a Rainin Microsorb-MV C-18 analytical column (5 microns, 250 × 4.6 mm) (Varian, Walnut Creek, CA) and Opti-Guard C-18 (1 mm) guard column (Optimize Technologies, Oregon City, OR). The mobile phase gradient began at 69:31 water/acetonitrile, increased linearly to 38:62 over 10 min, held for 2 min, returned to its initial composition over 3 min, and then re-equilibrated for 5 min. The flow rate was 1.75 ml/min. Injection volume was 20 μl. Analyte stock solutions were prepared in acetonitrile and used to formulate 4'-hydroxytolbutamide standards in urine for calibration curves (0.5–25 μg/ml, r² = 0.999). The intra-day coefficient of variation for 4'-hydroxytolbutamide was 2% at 0.5 and 25 μg/ml. All urine samples were analyzed on the same day.

Hydroxytolbutamide, carboxytolbutamide, and unchanged tolbutamide in urine were determined by HPLC after glucuronidase treatment using a modification of a previous method (Csillag et al., 1989). Briefly, urine (1 ml) containing 20 μg of chlorpropamide (internal standard) and 100 μl of 2 M HCl was twice extracted with 2 ml of diethyl ether by vortexing and was then centrifuged for 10 min at 2000g. The combined organic layers were evaporated to dryness under nitrogen at 40°C, reconstituted in 100 μl of methanol/acetonitrile/isopropanol (1:1:8) and transferred to autosampler vials. Analyses were performed at room temperature on an HP 1050 HPLC system with variable wavelength detector (235 nm) and a Rainin Microsorb-MV C-18 column (5 microns, 4.6 mm) (Varian, Walnut Creek, CA) and Opti-Guard C-18 (1 mm) guard column (Optimize Technologies, Oregon City, OR). The mobile phase gradient began at 69:31 water/acetonitrile, increased linearly to 38:62 over 10 min, held for 2 min, returned to its initial composition over 3 min, and then re-equilibrated for 5 min. The flow rate was 1.75 ml/min. Injection volume was 20 μl. Analyte stock solutions were prepared in acetonitrile and used to formulate 4'-hydroxytolbutamide standards in urine for calibration curves (0.5–25 μg/ml, r² = 0.999). The intra-day coefficient of variation for 4'-hydroxytolbutamide was 2% at 0.5 and 25 μg/ml. All urine samples were analyzed on the same day.

To verify that disulfiram had been ingested, subjects kept medication diaries, and urine was analyzed for 2-thiothiazolidine-4-carboxylic acid (TTCA), an established human biomarker for the major disulfiram metabolite carbon disulfide and also for disulfiram itself (van Doorn et al., 1981, 1982). TTCA was synthesized, and TTCA in urine was analyzed by gas chromatography-mass spectrometry, as described previously (Johnson et al., 1996). Briefly, 1 ml of filtered urine and 0.8 ml of 1 N HCl were extracted with 2 ml of ethyl acetate, dried over magnesium sulfate, evaporated to dryness, dissolved in methanol, derivatized with diazomethane, evaporated to dryness, reconstituted in acetonitrile, and analyzed by selected ion mode gas chromatography-mass spectrometry (m/z 132, M⁺ –COOCH₃). A linear standard curve was prepared using blank urine and TTCA (10–1000 ng/ml, r² > 0.99) and used for quantification. Urine samples were collected as described above and also for 0 to 24 h after midazolam.

Data Analysis. CYP2C9 activity was assessed by the tolbutamide metabolic ratio [(hydroxytolbutamide + carboxytolbutamide)/tolbutamide] in the 6 to 12-h urine (Veronese et al., 1990) and tolbutamide metabolite recovery (Peart, 1987). CYP2C19 activity was determined by the amount of 4'-hydroxytolbutamide excreted in the 0 to 8-h urine, expressed also as the hydroxylation index (μmol S-mephenytoin/μmol 4'-hydroxytolbutamide) (Kupper and Preisig, 1984; Wedlund et al., 1984; Xie et al., 1997). Individuals excreting <2% of the dose as 4'-hydroxytolbutamide were considered phenotypically poor metabolizers (Wedlund et al., 1984). The molar dextromethorphan/dextrophan metabolic ratio in 0 to 8-h urine was used to determine CYP2D6 activity (Schmid et al., 1985; Jacqz-Aigrain et al., 1993; Jones et al., 1996). A metabolic ratio >0.3 was considered evidence of CYP2D6 poor metabolizer phenotype (Schmid et al., 1985). Midazolam systemic clearance (dose/area under the curve) was determined by noncompartmental analysis (WinNonlin 1.5; Scientific Consulting, Inc. Cary, NC) and used as a measure of hepatic CYP3A4 activity (Thummel et al., 1994a, 1994b). Drug disposition in the control and disulfiram sessions was compared by paired t test or by Wilcoxon signed rank test if normality assumptions were violated. Significance was assigned at p < .05. Results are shown as the mean ± standard deviation.

Results

Mean midazolam plasma concentration versus time profiles in control and disulfiram-treated subjects were superimposable (Fig. 1A). Systemic clearance (670 ± 190 versus 700 ± 240 ml/min, p = .39) was similarly unchanged by disulfiram (Fig. 1B).

Dextromethorphan disposition in untreated subjects resembled that in previous reports (Jacqz-Aigrain et al., 1993; Ducharme et al., 1996; Jones et al., 1996). Urine excretion (0–8 h) of dextrophan, 3-methoxyxymorphinan, 3-hydroxymorphinan, and dextromethorphan was 27 ± 12, 0.05 ± 0.06, 14 ± 8, and 0.3 ± 0.5 μmol, respectively, representing 32 ± 15, 0.06 ± 0.07, 16 ± 10, and 0.3 ± 0.5% of the
phenotypic poor metabolizer. Average 4-hydroxymercaptoindole (6 – 12 h) of hydroxytolbutamide (104 ± 37 μmol; 56 ± 11% of the dose) excreted in 0 to 8-h urine, corresponding to a hydroxylation index of 1.9 ± 0.5. One subject could not void in the control phase, and two subjects were found to be poor metabolizers; these were excluded from the statistical analysis. Single-dose disulfiram effects on mephenytoin metabolism are shown in Fig. 3. No subject was converted to a phenotypically poor metabolizer. There was an excellent correlation (r = 0.94, not shown) between the two ratio measures of CYP2D6 activity, mephenytoin/dextrorphan and dextromethorphan/3-hydroxymorphinan, as described previously (Jones et al., 1996). The mean dextromethorphan/3-hydroxymorphinan metabolic ratio was also unchanged by disulfiram (0.028 ± 0.061 versus 0.032 ± 0.064, p = .22, data not shown). Dextromethorphan N-demethylation, another putative marker of CYP3A4 activity, was also unaffected by disulfiram pretreatment, with no change observed in the dextromethorphan/3-methoxymorphinan metabolic ratio (Fig. 2B). Neither molar excretion of dextromethorphan and metabolites nor metabolite recovery was significantly different after disulfiram pretreatment.

Mephenytoin metabolism in controls was similar to that described previously (Kupfer and Preisig, 1984; Xie et al., 1997), averaging 128 ± 25 μmol of 4'-hydroxymephenytoin (56 ± 11% of the dose) excreted in 0 to 8-h urine, corresponding to a hydroxylation index of 1.9 ± 0.5. One subject could not void in the control phase, and two subjects were found to be poor metabolizers; these were excluded from the statistical analysis. Single-dose disulfiram effects on mephenytoin metabolism are shown in Fig. 3. No subject was converted to a phenotypic poor metabolizer. Average 4'-hydroxymephenytoin excretion (122 ± 22 μmol; hydroxylation index 1.9 ± 0.4) was unchanged compared with controls (p = .72). In one subject, 4'-hydroxymephenytoin control excretion appeared low, although s/he was not a poor metabolizer. Reanalysis without this subject showed that 4'-hydroxymephenytoin excretion was somewhat lower after disulfiram (120 ± 22 versus 134 ± 18 μmol; hydroxylation index 2.0 ± 0.4 versus 1.7 ± 0.2, p = .045).

Tolbutamide metabolism in controls was similar to that described previously (Veronese et al., 1990, 1993), with one difference. Urine excretion (6–12 h) of hydroxytolbutamide (104 ± 37 μmol; 6 ± 2% of the dose), carboxytolbutamide (506 ± 179 μmol; 27 ± 10% of the dose), and percent of the dose recovered (33 ± 11%) were similar to those reported by Veronese et al. (4 ± 2, 22 ± 8, and 26 ± 9%) (1993). In contrast, urinary tolbutamide excretion (8.5 ± 4.6 μmol; 0.46 ± 0.25% of the dose) was higher than that reported previously (0.49 ± 0.23 μmol; 0.027 ± 0.013% of the dose) (Veronese et al., 1993). Consequently, the 6 to 12-h tolbutamide metabolic ratio we observed (84 ± 39) was lower than those reported previously (794 ± 87 and 1144 ± 529) (Veronese et al., 1990, 1993). This difference may be related in part to assay conditions. Urine tolbutamide concentrations were close to the limit of quantification for the HPLC-UV assay, as reported previously (Veronese et al., 1990). Thus, urine tolbutamide was re-assayed using liquid chromatography-mass spectrometry, which afforded greater sensitivity and specificity. Concentrations measured by liquid chromatography-mass spectrometry were approximately 2-fold greater than when measured by HPLC-UV and were used to calculate the tolbutamide metabolic ratio reported.

The effect of single-dose disulfiram on tolbutamide metabolism is shown in Fig. 4. Tolbutamide metabolite excretion was unchanged (577 ± 157 versus 610 ± 208 μmol, p = .54) after disulfiram pretreatment (Fig. 4A). The tolbutamide metabolic ratio, however, was slightly, although significantly, diminished after disulfiram (60 ± 17 versus 81 ± 40, p = .032), and this difference persisted after reanalysis without the subject with unusually low urine tolbutamide recovery (60 ± 18 versus 74 ± 26, p = .033) (Fig. 4B).
TTCA excretion after control and disulfiram pretreatment is shown in Fig. 5 for each isoform probe. TTCA was present in urine of untreated subjects, as described previously, due presumably to dietary sources (Simon et al., 1994). All subjects instructed to ingest disulfiram the night before probe drug administration, with the exception of one subject in the dextromethorphan study, showed increased TTCA excretion.

**Discussion**

Single-dose disulfiram effects on CYP3A4 activity, assessed by systemic midazolam clearance and dextromethorphan N-demethylation, can be compared against the influence of known CYP3A4 inhibitors. Neither midazolam clearance nor the dextromethorphan/3-methoxymorphinan metabolic ratio was affected by disulfiram pretreatment. In contrast, known CYP3A4 inhibitors such as macrolide antibiotics and azole antifungals markedly impair i.v. midazolam clearance (Olkkola et al., 1993, 1994; Kharasch et al., 1997). Furthermore, erythromycin pretreatment caused a significant 35 to 50% increase in the dextromethorphan/3-methoxymorphinan metabolic ratio (Ducharme et al., 1996; Jones et al., 1996). These results suggest that single-dose disulfiram does not significantly inhibit CYP3A4 activity in vivo. Lack of CYP3A4 inhibition, based on unaltered carbamazepine and methadone disposition, has also been seen with chronic disulfiram administration (Enghusen Poulsen et al., 1992).

Single-dose disulfiram effects on dextromethorphan O-demethylation can be compared against CYP2D6 activity in genetically deficient poor metabolizers and the effects of known CYP2D6 inhibitors. Phenotypic poor metabolizers have a dextrorphan/dextromethorphan metabolic ratio >0.3 (Schmid et al., 1985). In extensive metabolizers, the CYP2D6 inhibitor quinidine (1 week pretreatment) increased the dextromethorphan/dextromethorphan metabolic ratio from 0.015 ± 0.061 to 1.9 ± 1.6, and all subjects but one were converted from an extensive to a phenotypically poor metabolizer (Zhang et al., 1992). Similarly, a single quinidine dose administered to extensive metabolizers 12 h before dextromethorphan increased the average metabolic ratio from 0.005 to 0.4 (Schadel et al., 1995). In contrast, single-dose disulfiram did not significantly change the dextrophan/dextromethorphan metabolic ratio, and no subject was converted from an extensive to a poor metabolizer. Thus, these data suggest that single-dose disulfiram does not significantly inhibit CYP2D6 activity in vivo.

Single-dose disulfiram effects on S-mephenytoin hydroxylation can be compared against CYP2C19 activity in genetically deficient poor metabolizers and the effects of known CYP2C19 alternate substrates. Poor metabolizers excrete less than 1 to 5% of S-mephenytoin as 4′-hydroxymephenytoin (<2–11 μmol) (Wedlund et al., 1984; Sohn et al., 1992; Kubota et al., 1996; Xie et al., 1997). A single dose of chloroguanide increased the mephenytoin hydroxylation index from 1.4 ± 0.2 to 2.5 ± 1.8, corresponding to a reduction in 4′-hydroxymephenytoin excretion from 164 to 92 μmol (Partovian et al., 1995). A single dose of mephobarbital, administered shortly before mephenytoin, decreased S-mephenytoin clearance by approximately one-third.
involvement of CYP2C19 but not CYPs 2A6, 2C9, 2C19, 2D6, and 3A4. Second, single-dose disulfiram use to prevent CYP2E1-mediated drug or xenobiotic bioactivation is unlikely to result in untoward drug interactions resulting from inhibition of other P-450 isozymes and potentially hazardous alteration in therapeutic drug disposition.

Acknowledgment. We thank Tauri Senn for determination of midazolam pharmacokinetic parameters.

References


Los C-M, Day JD, Iue SG, Bush ED, Costello P, Dewey LV and Vestal RE (1989) Dose-